Compare ADMA Biologics Inc (ADMA) vs Snap On Incorporated (SNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Snap On Incorporated — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Snap On Incorporated trades at $400.31 (market cap $21.17B). The key difference: Snap On Incorporated is far larger — about 9.9× ADMA Biologics Inc's market cap, and Snap On Incorporated pays a 2.39% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SNA | |
|---|---|---|
Market Cap | $2.13B | $21.17B |
Sector | Health | Technology |
52-Week High | $20.38 | $413.62 |
52-Week Low | $7.60 | $313.01 |
Enterprise Value | $2.20B | $20.69B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Snap-on Incorporated (SNA) trades at $413.62, up 0.37% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.6% net income margin and recently beat Q4 2025 earnings. Recent acquisitions like Diesel Laptops for $100 million demonstrate strategic growth initiatives. Analyst consensus is positive with 65% buy ratings and a $407.50 price target.
SNA presents a stable investment with consistent dividend payments and share repurchases, though Q1 2026 earnings miss and elevated valuation ratios pose near-term risks. The stock's technical overbought condition suggests potential consolidation before further upside. Long-term growth depends on successful integration of acquisitions and maintaining premium margins in the competitive tools market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
